on 30 May 2023
Last Applicant/ Owned by
Babraham Research Campus Cambridge CB223
GB
Serial Number
79332232 filed on 12th Aug 2021
Registration Number
7064382 registered on 30th May 2023
Correspondent Address
Matthew L. Frisbee
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
Scientific and technological services, namely, research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory research services relating to the development of antibodies and antibody fragments; oncological research; research into the development of antibodies and antibody fragments; scientific and technological services, namely, provision of an Read More
Licensing of intellectual property, namely, licensing of research and development; licensing of intellectual property, namely, licensing of medical therapeutic research; licensing of intellectual property, namely, licensing of research relating to antibodies and antibody fragments; licensing of intellectual property, namely, licensing of research in relation to the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments; consultancy, advice and information relating to all of the aforesaid services
N/A
N/A
Scientific and technological services, namely, research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory research services relating to the development of antibodies and antibody fragments; oncological research; research into the development of antibodies and antibody fragments; scientific and technological services, namely, provision of antibodies and antibody fragments for medical and veterinary research and development in the field of chemicals, biologicals, antibodies and antibody fragments; engineering of antibodies and antibody fragments; scientific services, namely, discovery, preclinical and clinical development of therapeutic products; scientific research for others in the field of drug discovery, preclinical and clinical development of therapeutic and diagnostic products; research into antibodies, antibody fragments for others; research into the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments for others; consultancy, advice and information relating to all of the aforesaid services
N/A
N/A
Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic preparations that use monoclonal antibodies, namely therapeutic pharmaceutical for treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in the discovery, preclinical and clinical development of therapeutic products for medical and veterinary purposes; pharmaceutical preparations for use in oncology; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in oncology and therapeutic treatments in relation thereto
N/A
N/A
Chemicals used in industry and science; Chemicals for use in science and industry, namely, chemicals for laboratory research purposes; chemicals for use in science and industry, namely, chemicals for use in medical research; chemicals for use in science and industry, namely, chemicals for use in oncological research; antibodies and antibody fragments for scientific and laboratory use in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; laboratory chemicals, namely, antibody reagents used in cell and tissue assays for scientific and laboratory use; biochemicals, namely, monoclonal antibodies and antibody fragments for use in medical research; biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; molecules primarily comprised of antibodies and antibody fragments for use in medical research; molecules primarily comprised of antibodies and antibody fragments in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical development, clinical development and manufacture of therapeutic products
N/A
N/A
Custom manufacture of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments; custom manufacture of antibody and antibody fragments, for others, for use in medical therapies, including in relation to oncology; consultancy, advice and information relating to all of the aforesaid services
N/A
N/A
No 79332232
No Service Mark
No 315971USm0
No
No
No
No
Yes
Yes
No
No
Status Date | Action Taken |
---|---|
08th Nov 2024 | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED |
27th Oct 2023 | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED |
25th Sep 2023 | FINAL DECISION TRANSACTION PROCESSED BY IB |
31st Aug 2023 | FINAL DISPOSITION PROCESSED |
31st Aug 2023 | FINAL DISPOSITION NOTICE SENT TO IB |
30th Aug 2023 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
19th Aug 2023 | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED |
30th May 2023 | REGISTERED-PRINCIPAL REGISTER |
30th May 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
15th Mar 2023 | NOTIFICATION PROCESSED BY IB |